NYSE · EPC

Edgewell Personal Care Company

Consumer Defensive · Household & Personal Products

$26.88▼ 0.78% ($0.21)at close

As of 4:00 PM ET

52-week

$15.73$29.95

Market cap

$1.24B

What the market price implies · Reverse DCF

To support a price of $26.88, this model requires Stage 1 FCFF to grow by -15.59%/yr over the next 5 years, compounded annually.

Historical FCFF grew by -9.38%/yr over the past 10 years. The required annual growth rate is 6.21 percentage points lower.

Selected forecast · Base scenario

-9.38%/yr · Stage 1 default · years 1–5

Annual overrides take precedence over the Stage 1 default.

Market-implied · Other assumptions held fixed

-15.59%/yr · Stage 1 · years 1–5

Stage 1 growth is solved while Stage 2 growth, terminal growth, discount inputs, and annual overrides remain fixed. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Cash-flow DCF

Price used

$26.88

Estimated value / share

$44.58

Base scenario

This estimate is 65.87% above the price used.

USD · TTM ending 2026-06-30

Effective tax rate could not be derived — using 21% US default.

FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.

Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.

Market beta (0.40) is below the minimum default of 0.5 — short lookback windows can understate systematic risk. Beta floored at 0.5 for default assumptions; adjust manually if needed.

Stage 1 -9.38% · Stage 2 3.5% · Discount rate 5.77%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future free cash flow, discounted to its value today.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 12:28 PM UTC · provider

Why this method?

FCFF is positive, but the year-to-year swings are too large for a direct CAGR. Normalize the cash-flow base first, then run DCF.

Is FCFF positive and has it been for 3+ consecutive years? 29 consecutive positive FCFF years are available.

Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 128.8%.

Price vs Fundamentals

Why The Stock Is Moving

Momentum disconnected from fundamentalsModerate confidence

1Y Price: 24.04%Revenue (TTM): -7%FCF (TTM): 22.72%P/FCF: 85th pct

What changed

The stock rose 24.04% over the last year. Revenue declined 7% over the trailing twelve months. Operating margin moved from 6.96% to 1.66%. Free cash flow grew 22.72% over the trailing twelve months.

What the market seems to be pricing

The stock is rising despite deteriorating fundamentals and now sits at the 85th percentile of its historical P/FCF range. This is a momentum-driven move — the market may be front-running a recovery that has not yet appeared in reported numbers.

What would invalidate this read

Operating margin (currently 1.66%) would need to stabilize or improve to justify the move. Revenue is declining 7% — a trend reversal in the next report would be the key signal to watch. This read is wrong if the next period shows operating metrics turning the corner. At that point the price would be anticipating real improvement rather than running ahead of it.

Performance

Return analysis

Company profile

Edgewell Personal Care Company, along with its associated businesses, is a global producer and distributor of a diverse range of personal care items.

CEORod R. Little

SectorConsumer Defensive

IndustryHousehold & Personal Products

Employees6,700

IPO dateMar 27, 2000

https://edgewell.com

Market multiples

Forward P/E—

EV/EBITDA12.30

Enterprise value$2.28B

Stock splits

Jul 1, 2015↑ Forward

Every 1000 shares became 1349

+35%

Profitability & growth

Revenue growth-9.1%

Gross margin40.87%▼0.8ppvs FY2024

Operating margin1.66%▼4.5ppvs FY2024

ROE-6.16%▼7.8ppvs FY2025

Analyst consensus

RatingHold

Target price$29.83▲10.97%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 12, 2026

Q4 FY26 · EPS est $0.78 · Revenue est $479.48M

View

Dividends

$0.60/shareQuarterly5yr growth streakAdequate

EPC pays a dividend with a 2.23% dividend yield, 5 consecutive years of growth, covered 1.4× by free cash flow.

Dividend Yield

2.23%

Annual Div / Share

$0.60

5yr CAGR

+0%

Payout Ratio

115.35%

Adequate

Dividend Growth Rate

3yr CAGR

+0%

5yr CAGR

+0%

10yr CAGR

-7.18%

Dividend Safety

3/10Adequate

Dividend History

Annualized dividend cycles per share

YearAnnual DivYoY

2026$0.60+0.0%

2025$0.60+0.0%

2024$0.60+0.0%

2023$0.60+0.0%

2022$0.60+0.0%

2021$0.60-55.9%

2015$1.36-8.1%

Income Projection

Invest

Growth rate:

Reinvest dividends

Today

$22/yr

$2/mo

In 5 yrs

$22/yr

$2/mo

In 10 yrs

$22/yr

$2/mo

Today	In 5 yrs	In 10 yrs
$22/yr $2/mo	$22/yr $2/mo	$22/yr $2/mo

Analysis

Dividend Strengths

No strong strength signal stands out from the latest period pair.

Risks to Watch

High payout ratio

With 115.35% of earnings paid as dividends, there is limited retained earnings for reinvestment — and a dividend cut becomes more likely if earnings decline.

NYSE · EPC

Edgewell Personal Care Company

Consumer Defensive · Household & Personal Products

$26.88▼ 0.78% ($0.21)at close

As of 4:00 PM ET

52-week

$15.73$29.95

Market cap

$1.24B

What the market price implies · Reverse DCF

To support a price of $26.88, this model requires Stage 1 FCFF to grow by -15.59%/yr over the next 5 years, compounded annually.

Historical FCFF grew by -9.38%/yr over the past 10 years. The required annual growth rate is 6.21 percentage points lower.

Selected forecast · Base scenario

-9.38%/yr · Stage 1 default · years 1–5

Annual overrides take precedence over the Stage 1 default.

Market-implied · Other assumptions held fixed

-15.59%/yr · Stage 1 · years 1–5

Stage 1 growth is solved while Stage 2 growth, terminal growth, discount inputs, and annual overrides remain fixed. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Cash-flow DCF

Price used

$26.88

Estimated value / share

$44.58

Base scenario

This estimate is 65.87% above the price used.

USD · TTM ending 2026-06-30

Effective tax rate could not be derived — using 21% US default.

FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.

Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.

Market beta (0.40) is below the minimum default of 0.5 — short lookback windows can understate systematic risk. Beta floored at 0.5 for default assumptions; adjust manually if needed.

Stage 1 -9.38% · Stage 2 3.5% · Discount rate 5.77%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future free cash flow, discounted to its value today.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 12:28 PM UTC · provider

Why this method?

FCFF is positive, but the year-to-year swings are too large for a direct CAGR. Normalize the cash-flow base first, then run DCF.

Is FCFF positive and has it been for 3+ consecutive years? 29 consecutive positive FCFF years are available.

Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 128.8%.

Price vs Fundamentals

Why The Stock Is Moving

Momentum disconnected from fundamentalsModerate confidence

1Y Price: 24.04%Revenue (TTM): -7%FCF (TTM): 22.72%P/FCF: 85th pct

What changed

The stock rose 24.04% over the last year. Revenue declined 7% over the trailing twelve months. Operating margin moved from 6.96% to 1.66%. Free cash flow grew 22.72% over the trailing twelve months.

What the market seems to be pricing

What would invalidate this read

Performance

Return analysis

Company profile

Edgewell Personal Care Company, along with its associated businesses, is a global producer and distributor of a diverse range of personal care items.

CEORod R. Little

SectorConsumer Defensive

IndustryHousehold & Personal Products

Employees6,700

IPO dateMar 27, 2000

https://edgewell.com

Market multiples

Forward P/E—

EV/EBITDA12.30

Enterprise value$2.28B

Stock splits

Jul 1, 2015↑ Forward

Every 1000 shares became 1349

+35%

Profitability & growth

Revenue growth-9.1%

Gross margin40.87%▼0.8ppvs FY2024

Operating margin1.66%▼4.5ppvs FY2024

ROE-6.16%▼7.8ppvs FY2025

Analyst consensus

RatingHold

Target price$29.83▲10.97%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 12, 2026

Q4 FY26 · EPS est $0.78 · Revenue est $479.48M

View

Dividends

$0.60/shareQuarterly5yr growth streakAdequate

EPC pays a dividend with a 2.23% dividend yield, 5 consecutive years of growth, covered 1.4× by free cash flow.

Dividend Yield

2.23%

Annual Div / Share

$0.60

5yr CAGR

+0%

Payout Ratio

115.35%

Adequate

Dividend Growth Rate

3yr CAGR

+0%

5yr CAGR

+0%

10yr CAGR

-7.18%

Dividend Safety

3/10Adequate

Dividend History

Annualized dividend cycles per share

YearAnnual DivYoY

2026$0.60+0.0%

2025$0.60+0.0%

2024$0.60+0.0%

2023$0.60+0.0%

2022$0.60+0.0%

2021$0.60-55.9%

2015$1.36-8.1%

Income Projection

Invest

Growth rate:

Reinvest dividends

Today

$22/yr

$2/mo

In 5 yrs

$22/yr

$2/mo

In 10 yrs

$22/yr

$2/mo

Today	In 5 yrs	In 10 yrs
$22/yr $2/mo	$22/yr $2/mo	$22/yr $2/mo

Analysis

Dividend Strengths

No strong strength signal stands out from the latest period pair.

Risks to Watch

High payout ratio

With 115.35% of earnings paid as dividends, there is limited retained earnings for reinvestment — and a dividend cut becomes more likely if earnings decline.